Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies

Qëndresë Daka, Nina Špegel, Makedonka Atanasovska Velkovska, Tjaša Steblovnik, Miriam Kolko, Burim Neziri, Barbara Cvenkel*

*Corresponding author af dette arbejde

Abstract

A short-term increase in intraocular pressure (IOP) is a common side effect after intravitreal anti-VEGF therapy, but a sustained increase in IOP with the development of secondary glaucoma has also been reported in some studies after repeated intravitreal anti-VEGF injections. The aim of this review is to present and discuss the possible pathophysiological mechanisms and factors contributing to a sustained rise in IOP, as well as treatment strategies for patients at risk. Close monitoring and adjustable IOP-lowering treatment are recommended for high-risk patients, including those with glaucoma, angle-closure anomalies, ocular hypertension or family history of glaucoma; patients receiving a high number of injections or at shorter intervals; and patients with capsulotomy. Strategies are needed to identify patients at risk in a timely manner and to prevent sustained elevation of IOP.

OriginalsprogEngelsk
Artikelnummer4674
TidsskriftJournal of Clinical Medicine
Vol/bind12
Udgave nummer14
ISSN2077-0383
DOI
StatusUdgivet - 14 jul. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies'. Sammen danner de et unikt fingeraftryk.

Citationsformater